Creating MHC-restricted neoantigens with covalent inhibitors that can be targeted by immune therapy
Intracellular oncoproteins can be inhibited with targeted therapy, but responses are not
durable. Immune therapies can be curative, but most oncogene-driven tumors are …
durable. Immune therapies can be curative, but most oncogene-driven tumors are …
Combined inhibition of SHP2 and CXCR1/2 promotes antitumor T-cell response in NSCLC
Abstract SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in
multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in …
multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in …
[PDF][PDF] Combined Inhibition of SHP2 and CXCR1/2 Promotes Anti-Tumor T Cell Response in NSCLC
Clinical trials of SHP2 inhibitors (SHP2i) alone and in various combinations are ongoing for
multiple tumors with over-activation of the RAS/ERK pathway. SHP2 plays critical roles in …
multiple tumors with over-activation of the RAS/ERK pathway. SHP2 plays critical roles in …
[PDF][PDF] Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS mutant cancers
J Silver, G Caponigro, DD Stuart, TJ Abrams… - researchgate.net
KRAS, an oncogene mutated in nearly one-third of human cancers, remains a
pharmacological challenge for direct inhibition except for recent advances in selective …
pharmacological challenge for direct inhibition except for recent advances in selective …